Unicycive Therapeutics (UNCY) to Release Quarterly Earnings on Monday

Unicycive Therapeutics (NASDAQ:UNCY) is projected to release its results before the market opens on Monday, March 30th. Analysts expect Unicycive Therapeutics to post earnings of ($0.46) per share for the quarter.

Unicycive Therapeutics Trading Down 1.2%

Shares of NASDAQ UNCY opened at $6.73 on Monday. The company has a 50 day simple moving average of $6.63 and a two-hundred day simple moving average of $5.66. The stock has a market cap of $144.63 million, a price-to-earnings ratio of -1.70 and a beta of 1.82. Unicycive Therapeutics has a 12 month low of $3.71 and a 12 month high of $11.00.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Monday, December 29th. Guggenheim reaffirmed a “buy” rating on shares of Unicycive Therapeutics in a research report on Tuesday, December 30th. Finally, Westpark Capital initiated coverage on Unicycive Therapeutics in a research note on Thursday, February 19th. They set a “buy” rating for the company. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $34.33.

Hedge Funds Weigh In On Unicycive Therapeutics

Institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new stake in Unicycive Therapeutics during the fourth quarter worth $226,000. Millennium Management LLC purchased a new stake in Unicycive Therapeutics during the fourth quarter worth $5,856,000. Cantor Fitzgerald L. P. acquired a new stake in Unicycive Therapeutics during the fourth quarter valued at $1,154,000. OMERS ADMINISTRATION Corp purchased a new position in Unicycive Therapeutics in the fourth quarter valued at $451,000. Finally, State Street Corp increased its holdings in Unicycive Therapeutics by 19.0% in the fourth quarter. State Street Corp now owns 65,227 shares of the company’s stock valued at $376,000 after buying an additional 10,400 shares in the last quarter. 40.42% of the stock is owned by hedge funds and other institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.